Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GlaxoSmithKline and Synta Pharmaceuticals have executed a global collaboration agreement for the joint development and commercialization of a first-in-class, small-molecule, oxidative stress inducer which is entering Phase III clinical development for the treatment of metastatic melanoma.
Subscribe to our email newsletter
Under the terms of the agreement, the companies will share responsibility for development and commercialization of the oxidative stress inducer, STA-4783, in the US. GlaxoSmithKline (GSK) will have responsibility for development and commercialization of STA-4783 outside the US, while Synta will receive an upfront cash payment of $80 million.
Synta and GSK will jointly commercialize STA-4783 in the US with Synta receiving a tiered profit share based on levels of annual net sales. The parties will share development costs outside of the US and Synta will receive double-digit tiered royalties on net sales.
Safi Bahcall, president and CEO, Synta, said: “GSK and Synta have a shared vision for the development and commercialization of STA-4783 in a range of potential indications, beginning with metastatic melanoma where a Phase IIb study with STA-4783 in combination with Paclitaxel has shown doubling of progression free survival compared to Paclitaxel alone.”
Moncef Slaoui, chairman of R&D, GSK, said: “This agreement further strengthens our late-stage oncology pipeline, which currently includes ten Phase III programs, and also demonstrates our commitment to identifying compounds that have the potential to deliver real benefit to patients.”